Frontlight ResearchEarly access
CompletedPhase 3
The Celljuvant study, A phase 3 Immunogenicity and Safety Study of aQIVc HD Vaccine in Adults aged 50 years and older.
Key facts
- Who runs it
- Seqirus UK Limited
- Where
- Denmark, Estonia, and Germany26 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 2,100 people enrolled
- Started
- 3 Nov 2023
- Ended
- 16 May 2025
- Type of study
- Interventional
- Record updated
- 27 September 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Individuals, aged 50 years and older, who are healthy or have stable comorbidities that increase their risk of complications from influenza infection
- Individuals who can comply with all study procedures
Who cannot take part
- Influenza vaccination within 180 days prior to informed consent or plan to receive influenza vaccine within 9 months from study vaccination (all subjects) or within 12 months (subjects in the long-term subset for immunogenicity)
- Progressive, unstable, or uncontrolled clinical conditions
- Known hypersensitivity or allergy to any study vaccine component
- Known history of Guillain-Barré syndrome or other demyelinating disease
- Condition representing a contraindication to vaccination or blood draw
- Abnormal function of immune system due to know disorder or medication
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To demonstrate in a sequential manner: First, clinical lot-to-lot consistency of 3 consecutive aQIVc HD lots, in terms of immunogenicity for each vaccine strain in subjects aged 50 years and older, as measured by hemagglutination inhibition (HI)* assay using cell-derived target viruses, at Day 29. Then, immunological noninferiority of aQIVc HD vs QIVr and vs aQIV for each vaccine strain in subjects aged 50 years and older, as measured by HI* geometric mean titers (GMTs) and seroconversion rates (SCRs), using cell-derived target viruses, at Day 29.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Observer-Blind, Controlled, Multicenter, Clinical Study to Evaluate Immunogenicity and Safety of a High-Dose MF59-Adjuvanted Quadrivalent Subunit Cell-derived Influenza Vaccine (aQIVc HD) in Comparison with a Non-adjuvanted Quadrivalent Recombinant Influenza Vaccine (QIVr) and an MF59-Adjuvanted Quadrivalent Subunit Egg-derived Influenza Vaccine (aQIV), in Adults Aged 50 Years and Older.
- Record updated
- 27 September 2024